Want to see FNCHQ full AI Analyst Report?

Finch Therapeutics Group (FNCHQ) Price & Analysis

64 Followers

FNCHQ Stock Chart & Stats

$7.66

-$0.05(-0.45%)

At close: Jan 08 4:00 PM EST

$7.66

-$0.05(-0.45%)

Day’s Range― - ―

52-Week Range$2.00 - $16.10

Previous CloseN/A

VolumeN/A

Average Volume (3M)6.04K

Market Cap

$16.06M

Enterprise Value$12.98

Total Cash (Recent Filing)$16.04M

Total Debt (Recent Filing)$28.99M

Price to Earnings (P/E)―

Beta1.52

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,605,763

10 Day Avg. Volume2,609

30 Day Avg. Volume6,039

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.25

Price to Sales (P/S)54.13

P/FCF Ratio-0.18

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Unique PlatformThe company's unique platform for microbiome therapy development provides a competitive advantage, potentially leading to innovative treatments and long-term growth opportunities.

Partnerships And CollaborationsStrategic partnerships and collaborations provide Finch Therapeutics with diverse revenue streams and access to additional resources, enhancing its ability to innovate and expand its market presence.

Improved Stockholder EquityThe improvement in stockholder equity indicates a strengthening financial position, which can enhance investor confidence and provide a foundation for future growth.

Bears Say

Persistent LossesOngoing financial losses and high leverage pose significant risks to Finch Therapeutics' sustainability, potentially limiting its ability to invest in growth and innovation.

Negative Cash FlowsNegative cash flows highlight inefficiencies in operations and raise concerns about the company's ability to sustain its activities without external financing.

Declining RevenuesDeclining revenues reflect challenges in market demand or competitive positioning, which could hinder Finch Therapeutics' ability to achieve profitability and long-term growth.

FNCHQ FAQ

What was Finch Therapeutics Group’s price range in the past 12 months?

Finch Therapeutics Group lowest stock price was $2.00 and its highest was $16.10 in the past 12 months.

What is Finch Therapeutics Group’s market cap?

Finch Therapeutics Group’s market cap is $16.06M.

When is Finch Therapeutics Group’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Finch Therapeutics Group’s earnings last quarter?

Currently, no data Available

Is Finch Therapeutics Group overvalued?

According to Wall Street analysts Finch Therapeutics Group’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Finch Therapeutics Group pay dividends?

Finch Therapeutics Group does not currently pay dividends.

What is Finch Therapeutics Group’s EPS estimate?

Finch Therapeutics Group’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Finch Therapeutics Group have?

Finch Therapeutics Group has 1,605,763 shares outstanding.

What happened to Finch Therapeutics Group’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Finch Therapeutics Group?

Currently, no hedge funds are holding shares in FNCHQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Finch Therapeutics Group

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.